Free Newsletter
BU team offers up a new lung cancer target
A group of researchers at Boston University has mapped out key new insights into the command and control center of cancer cells, offering a new approach to identifying cancer cells and targeting them with new treatments.
"Identifying the phosphorylation status of proteins in cancer cells versus normal cells provides us with a unique ability to understand and perhaps intervene with the command and control center of cancer cells," said co-senior study author Professor Simon Kasif. And targeting a specific collection of proteins would potentially offer an effective therapy for all types of lung cancers, say the researchers.
"This is the first statistically validated phosphopeptide signature to diagnose any disease, much less cancer or lung cancer," added senior co-author Dr. Martin Steffen.
- read the UPI story
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: